Rafael G. dos Santos, Francisco S. Guimarães, José Alexandre S. Crippa, Jaime E. C. Hallak, Giordano Novak Rossi, Juliana Mendes Rocha, Antônio W. Zuardi

Published in Expert Opinion on Drug Metabolism & Toxicology

9 April 2020



Introduction: Recent trials using cannabidiol (CBD) have shown that most acute and prolonged adverse effects of CBD are mild to moderate, with rare serious adverse effects (SAEs). This review focused on analyzing SAEs of CBD and their possible relation to drug-drug interactions.Areas covered: We systematically analyzed the SAEs reported in randomized controlled trials (RCTs) involving the administration of oral CBD for at least one week in both healthy volunteers and clinical samples.Expert opinion: SAEs related to CBD in RCT are rare and include mainly elevated transaminases, convulsion, sedation, lethargy, and upper respiratory trait infections. Elevated transaminases are related to concomitant valproate use, while sedation, lethargy, and upper respiratory trait infections are related to concomitant clobazam use. Epileptic patients should be monitored when using CBD concomitantly with these and other antiepileptic drugs for other possible drug-drug interactions.


DOI: 10.1080/17425255.2020.1754793



dos Santos RG, Guimarães FS, Crippa JAS, et al. Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Expert Opin Drug Metab Toxicol. April 2020:17425255.2020.1754793. doi:10.1080/17425255.2020.1754793